You are here: Industry Insights > GSK

News List

GSK boosts Benlysta production with $139 million investment pharmafile
May 08, 2017
GSK has announced that it will invest $139 million into increasing production capacity at its Rockville...
GSK invests $139m to increase Benlysta (belimumab) production capacity pharmaceutical-technology
May 05, 2017
GSK is investing $139m in its biopharmaceutical manufacturing site located in Rockville, Maryland, to expand the production of Benlysta (belimumab).
Epizyme Earns $10 Million Payment from GSK for GLP Toxicology Studies americanpharmaceuticalreview
May 05, 2017
Epizyme announced it earned a $10 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK’s initiation of GLP toxicology studies for a methyltransferase inhibitor discovered by Epizyme and licensed to GSK.
Epizyme Earns $10M GSK Milestone contractpharma
May 05, 2017
Initiates GLP tox studies with novel methyltransferase inhibitor
GSK Invests $139M to Expand BENLYSTA Capacity contractpharma
May 03, 2017
Will provide additional capacity to increase bulk drug substance production by nearly 50% in Rockville, MD
Mixed first quarter fortunes for GSK, AZ pharmatimes
April 28, 2017
GlaxoSmithKline saw its first-quarter sales leap nearly 20 percent as growth across all of its key businesses was given a significant helping hand by currency effects.
Teva launches competitors to GSK’s Advair inhaler pharmafile
April 24, 2017
GSK has been anticipating competition to its Advair for two years and Teva has announced that it will be...
GSK and Daiichi Sankyo JV submits NDA for candidate shingles vaccine in Japan pharmaceutical-technology
April 21, 2017
GlaxoSmithKline (GSK) and Daiichi Sankyo joint venture (JV) Japan Vaccine Co has submitted a New Drug ...
GSK vaccine R&D exec: Get to work now on the next emerging disease outbreak fiercepharma
April 12, 2017
Caught off guard by deadly outbreaks such as Ebola and Zika, experts now say the current process of developing emerging-disease vaccines needs a shakeup. Here's what GlaxoSmithKline’s U.S. vaccine R&D head Ripley Ballou has in mind.
Breathing space for GSK as Mylan’s Advair copy rejected pharmaphorum
March 31, 2017
GSK can breathe easy as new CEO Emma Walmsley takes over, following the FDA rejection of Mylan’s generic version of big-selling respiratory drug Advair.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page